Clinical Trial Update: A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase I clinical trial of Y150 in relapsed or refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Y150

Snippet

Sponsor: Wuhan YZY Biopharma Co., Ltd. | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 1 | Status: COMPLETED